Stock Market Reviews

Read and share opinions on FTRE (Fortrea Holdings Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Why Fortrea (FTRE) Stock Is Up Today
  Dec 19, 2025
• Fortrea (FTRE): Reassessing Valuation After a Sharp 3-Month Share Price Rebound
  Dec 19, 2025
• Why Fortrea (FTRE) Stock Is Trading Up Today
  Dec 18, 2025
• Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
  Dec 10, 2025
• Fortrea (FTRE) Valuation Check After Investigation into Alleged Overstated Revenue, Cost Savings, and 2025 EBITDA Targets
  Dec 3, 2025
• Fortrea (FTRE) Stock Trades Up, Here Is Why
  Nov 25, 2025
• Fortrea to Present at Upcoming Citi and Evercore Healthcare Conferences
  Nov 25, 2025
• Fortrea Completes $75.7 Million Senior Notes Tender Offer Utilizing Cash on Hand
  Nov 24, 2025
• Fortrea Appoints Agnieszka Gallagher as General Counsel
  Nov 17, 2025
• Fortrea Holdings (FTRE): Evaluating Valuation After Q3 Earnings Beat and Raised 2025 Revenue Guidance
  Nov 14, 2025

FTRE News

• 3 Inflated Stocks with Open Questions
  Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.
  Dec 29, 2025
• 3 Stocks Under $50 Walking a Fine Line
  The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
  Dec 25, 2025
• Why Fortrea (FTRE) Stock Is Up Today
  Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) jumped 8% in the afternoon session after an analyst at Mizuho raised the firm's price target on the stock while maintaining a Neutral rating.
  Dec 19, 2025
• Fortrea (FTRE): Reassessing Valuation After a Sharp 3-Month Share Price Rebound
  Fortrea Holdings (FTRE) has quietly shifted gears, with the share price jumping about 65% over the past month and roughly 64% in the past 3 months, reversing earlier weakness. See our latest analysis for Fortrea Holdings. That surge sits against a tougher backdrop, with the year to date share price return still negative and the 1 year total shareholder return down double digits. This suggests sentiment has quickly shifted toward a recovery story. If Fortrea’s sharp rebound has you thinking...
  Dec 19, 2025
• Why Fortrea (FTRE) Stock Is Trading Up Today
  Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) jumped 5.7% in the morning session after an analyst at Mizuho raised the company's price target. Analyst Ann Hynes reaffirmed a neutral stance on Fortrea Holdings but increased the price target to $13.00 from a previous $11.00.
  Dec 18, 2025
• Why Fortrea (FTRE) Stock Is Up Today
  Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) jumped 6.2% in the afternoon session after Citigroup upgraded the stock's rating to Buy from Neutral and significantly raised its price target. The analyst firm increased its price target by 75%, from $12.00 to $21.00. This positive shift reflected the firm's renewed confidence in Fortrea Holdings' market performance and future prospects, according to the analyst report.
  Dec 11, 2025
• Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
  DURHAM, N.C., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization, today announced the granting of an inducement award of restricted stock units (“RSUs”) on December 10, 2025, to two newly hired employees. The award consisted of 245,000 RSUs that vest in three equal annual installments starting December 10, 2026, subject to the employee’s continuous employment through the applicable vesting date. The RSUs are subject to the te
  Dec 10, 2025
• SCTbio and Fortrea Forge Strategic Collaboration to Accelerate Cell and Gene Therapy Development and Delivery
  PRAGUE, Czech Republic and DURHAM, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- SCTbio, a leading European CDMO specializing in GMP manufacturing for cell-based products, and Fortrea, a leading global contract research organization (CRO), today announced a strategic collaboration agreement between the two companies. This partnership aims to streamline development, accelerate timelines and bring advanced therapies to patients faster. This collaboration represents a forward-looking model for how CDMOs
  Dec 4, 2025
• Fortrea (FTRE) Valuation Check After Investigation into Alleged Overstated Revenue, Cost Savings, and 2025 EBITDA Targets
  Fortrea Holdings (FTRE) is back in the spotlight after a shareholder rights firm launched an investigation into whether management overstated revenue, cost savings, and 2025 EBITDA goals, raising fresh questions about its post spin off story. See our latest analysis for Fortrea Holdings. That backdrop helps explain why, despite a sharp 1 month share price return of about 26 percent and a 90 day share price gain above 20 percent off the lows, Fortrea’s year to date share price return remains...
  Dec 3, 2025
• Does Fortrea’s (FTRE) Debt Buyback Mark a Shift in Its Post-Divestiture Financial Strategy?
  Fortrea Holdings recently completed a debt tender offer to repurchase US$75.74 million of its 7.500% Senior Secured Notes due 2030, reducing the outstanding principal in connection with earlier business divestitures finalized in June 2024. This action fulfills debt reduction commitments linked to its past divestitures and may enhance Fortrea’s financial flexibility for future operations. We’ll explore how Fortrea’s substantial reduction in outstanding debt influences the company's investment...
  Nov 26, 2025
• Fortrea (FTRE) Stock Trades Up, Here Is Why
  Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) jumped 10.2% in the afternoon session after the company announced it completed a debt tender offer, purchasing approximately $75.7 million of its outstanding senior secured notes.
  Nov 25, 2025
• Fortrea to Present at Upcoming Citi and Evercore Healthcare Conferences
  DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that chief executive officer, Anshul Thakral, chief financial officer, Jill McConnell, and senior vice president of investor relations, Tracy Krumme, will participate in the following conferences in December: Citi Global Healthcare Conference (Miami)Date:Tuesday, December 2, 2025Time:1:00 pm ETFormat:Fireside ChatWebcast:FTRE Citi webcast Evercore 8th Ann
  Nov 25, 2025
• BrightSpring Health Services, 10x Genomics, QuidelOrtho, Medpace, and Fortrea Shares Are Soaring, What You Need To Know
  A number of stocks jumped in the afternoon session after reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies. These subsidies, which are government financial aids to help people pay for health insurance, are crucial for insurers as they maintain a stable customer base. An extension would ensure continued revenue for companies with significant exposure to the ACA marketplace. The news prompted a strong positive reaction from investors, with Cente
  Nov 25, 2025
• Fortrea Completes $75.7 Million Senior Notes Tender Offer Utilizing Cash on Hand
  DURHAM, N.C., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it has completed its debt tender offer (the “Tender Offer”) described in the Offer to Purchase dated October 20, 2025 by purchasing $75,743,000 in aggregate of the Company’s outstanding 7.500% Senior Secured Notes due 2030 (CUSIP No. 34965K AA5 (Rule 144A); U31685 AA5 (Reg S)) (each, a “Note” and collectively, the “Notes”). The Tender
  Nov 24, 2025
• NeoGenomics, Fortrea, and Acadia Healthcare Shares Skyrocket, What You Need To Know
  A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to
  Nov 21, 2025
• What Catalysts Are Shifting the Story for Fortrea Holdings?
  Fortrea Holdings has seen its consensus analyst price target raised from $9.53 to $11.21. This signals a notable shift in market sentiment. This adjustment reflects renewed confidence among analysts, fueled by operational resilience and an improved business outlook despite ongoing leadership changes. Read on to discover how investors can track these evolving perspectives and stay informed about future shifts in Fortrea Holdings’ narrative. Stay updated as the Fair Value for Fortrea Holdings...
  Nov 17, 2025
• Fortrea Appoints Agnieszka Gallagher as General Counsel
  DURHAM, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced the appointment of Agnieszka (Aggie) M. Gallagher as general counsel. Gallagher is responsible for the Company’s legal strategy and operations, serving as corporate secretary, chief compliance officer and as a member of Fortrea’s leadership team. She succeeds J. Stillman Hanson, who is leaving the Company after a planned transition period.
  Nov 17, 2025
• 1 Healthcare Stock to Consider Right Now and 2 Facing Headwinds
  Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s 11.6% return has trailed the S&P 500 by 4.7 percentage points.
  Nov 14, 2025
• Fortrea Holdings (FTRE): Evaluating Valuation After Q3 Earnings Beat and Raised 2025 Revenue Guidance
  Fortrea Holdings (FTRE) just released its third quarter earnings, showing improved sales and a smaller net loss compared to last year. The company also raised its full-year 2025 revenue outlook, catching investors’ attention. See our latest analysis for Fortrea Holdings. After a challenging start to the year, Fortrea’s momentum has been shifting. While the year-to-date share price return sits at -45.2%, shares have rebounded with a 27.1% gain over the past three months. The recent bump...
  Nov 14, 2025
• Q3 Earnings Highs And Lows: Fortrea (NASDAQ:FTRE) Vs The Rest Of The Drug Development Inputs & Services Stocks
  The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Fortrea (NASDAQ:FTRE) and the rest of the drug development inputs & services stocks fared in Q3.
  Nov 12, 2025
• 5 Insightful Analyst Questions From Fortrea’s Q3 Earnings Call
  Fortrea’s third quarter results were met with a significant positive response from the market, as robust demand across its clinical pharmacology and clinical development businesses drove revenue growth. Management highlighted that win rates with biotech clients doubled compared to the prior quarter, and strong RFP volumes led to new business wins in both new and repeat clients. CEO Anshul Thakral credited operational improvements, noting, “Our win rates improved significantly, reaching the highe
  Nov 12, 2025
• Velocity Clinical Research Appoints Former Fortrea Executive, Andrew Reina, as Chief Revenue Officer
  Firm to target small to medium-sized biotech and pharma companies Drew Reina, CRO at Velocity Clinical Research Drew Reina, CRO at Velocity Clinical Research DURHAM, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Velocity Clinical Research (Velocity), the leading fully integrated site organization, today announces the appointment of Andrew (Drew) Reina as Chief Revenue Officer (CRO), effective immediately. Drew joins from Fortrea, one of the world’s leading contract research organizations (CROs), where
  Nov 12, 2025
• Elevance Health, Labcorp, Privia Health, Fortrea, and Amgen Shares Are Soaring, What You Need To Know
  A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.
  Nov 11, 2025
• Fortrea Holdings (FTRE) Is Up 7.6% After Raising 2025 Revenue Outlook on Strong Q3 Results - Has the Bull Case Changed?
  Fortrea Holdings reported results for the third quarter of 2025, exceeding revenue expectations with US$701.3 million in sales and revising full-year revenue guidance upward to a range of US$2.7 billion to US$2.75 billion. This announcement highlights strong demand and improved client win rates, alongside continued progress on technology and cost-saving initiatives in the competitive clinical research industry. We’ll consider how the raised revenue guidance and robust backlog enhance Fortrea...
  Nov 8, 2025
• FTRE Q3 Deep Dive: Revenue Outpaces Estimates, Margin Expansion Remains a Focus
  Clinical research company Fortrea Holdings (NASDAQ:FTRE) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 3.9% year on year to $701.3 million. The company’s full-year revenue guidance of $2.73 billion at the midpoint came in 3.1% above analysts’ estimates. Its non-GAAP profit of $0.12 per share was 22.8% below analysts’ consensus estimates.
  Nov 6, 2025
• Fortrea Holdings (FTRE): Widening Losses at 52.8% Annually Challenge Value Bull Narratives
  Fortrea Holdings (FTRE) reported ongoing losses, with net losses having widened at a steep 52.8% per year over the last five years, and profitability not expected for at least another three. Revenue is forecast to grow at just 2.4% annually, trailing the broader US market’s 10.5% average. Despite these persistent losses and no signs of margin improvement, the company’s shares are trading at $11.95, well below an estimated fair value of $18.73 as well as peer valuation multiples. This...
  Nov 6, 2025
• Fortrea Holdings Inc. (FTRE) Q3 Earnings Lag Estimates
  Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of -25.00% and +9.21%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 5, 2025
• Fortrea Holdings Inc (FTRE) Q3 2025 Earnings Call Highlights: Strong Demand and Strategic ...
  Fortrea Holdings Inc (FTRE) reports solid revenue and improved win rates, while navigating competitive pricing and margin pressures.
  Nov 5, 2025
• Fortrea (NASDAQ:FTRE) Beats Q3 Sales Expectations
  Clinical research company Fortrea Holdings (NASDAQ:FTRE) announced better-than-expected revenue in Q3 CY2025, with sales up 3.9% year on year to $701.3 million. The company’s full-year revenue guidance of $2.73 billion at the midpoint came in 3.1% above analysts’ estimates. Its non-GAAP profit of $0.12 per share was 25.7% below analysts’ consensus estimates.
  Nov 5, 2025
• Why Fortrea (FTRE) Stock Is Trading Up Today
  Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) jumped 25.3% in the morning session after the company reported third-quarter financial results that showed stronger-than-expected revenue and an improved outlook for the full year. For the third quarter, Fortrea announced revenues of $701.3 million, which surpassed analyst estimates. However, its adjusted earnings of $0.12 per share fell short of projections. Despite the mixed bottom-line results, investors appeared to focus on t
  Nov 5, 2025
• Fortrea Reports Third Quarter 2025 Results
  For the three months ended September 30, 2025, from continuing operations: Revenues of $701.3 millionGAAP net loss of $(15.9) millionAdjusted EBITDA of $50.7 millionGAAP and adjusted net (loss) income per diluted share of $(0.17) and $0.12, respectivelyBook-to-bill ratio of 1.13x, resulting in 1.07x book-to-bill for the trailing 12 monthsCost saving initiatives remain on trackRaising 2025 revenue guidance to a range of $2,700 million to $2,750 million; narrowing 2025 adjusted EBITDA guidance to
  Nov 5, 2025
• Fortrea (FTRE) Reports Q3: Everything You Need To Know Ahead Of Earnings
  Clinical research company Fortrea Holdings (NASDAQ:FTRE) will be announcing earnings results this Wednesday morning. Here’s what to expect.
  Nov 4, 2025
• Why The Narrative Around Fortrea Holdings Is Shifting Amid New Analyst and Business Updates
  Fortrea Holdings stock has seen its fair value price target inch upward, moving from $9.44 to $9.53 following recent analyst updates. This modest increase reflects nuanced changes in how experts view the company's prospects as they weigh both encouraging and challenging signals. Stay tuned to discover how investors can follow the evolving story, with new data and outlooks continuing to reshape the narrative in the months ahead. Stay updated as the Fair Value for Fortrea Holdings shifts by...
  Nov 2, 2025
• 3 Inflated Stocks We Find Risky
  Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.
  Oct 31, 2025
• Exploring October 2025's Top Undervalued Small Caps With Insider Activity
  As the U.S. stock market continues to reach new heights, with major indices like the S&P 500 and Nasdaq setting fresh records, investors are keenly observing how small-cap stocks might benefit from these broader trends. In this environment of solid corporate earnings and potential interest rate cuts by the Federal Reserve, identifying small-cap stocks with strong fundamentals and insider activity could present unique opportunities for growth-oriented investors.
  Oct 29, 2025

FTRE Reviews

• MarketMyth

  Dec 30, 2025

  $FTRE Amidst changing market dynamics, this entity shows a commitment to innovation within its sector. Their focus on strategic partnerships is likely to enhance future prospects.

  Buy

• GainVector

  Dec 29, 2025

  $FTRE This organization is leveraging its unique position in the market to capitalize on growth opportunities. Its forward-thinking strategies are likely to appeal to investors looking for stability and innovation.

  Buy

• CapitalVortex

  Dec 29, 2025

  $FTRE Every report brings a jolt of adrenaline, leaving investors in a whirlwind of uncertainty. What's next? The suspense is absolutely excruciating!

  Buy

• DividendDemon

  Dec 29, 2025

  $FTRE This company gives a whole new meaning to 'holding on tight'—like your mom's grip on your arm at the mall!

  Sell

• TheChartCode

  Dec 29, 2025

  $FTRE With this company, you're not just getting a good deal; you're getting an entire episode of 'How I Met Your Stock!'

  Buy

• CapitalFrame

  Dec 28, 2025

  $FTRE With a focused approach on customer satisfaction and expansion, this firm is likely to capture additional market opportunities. The fundamentals suggest a promising future.

  Buy

• MarketSavage

  Dec 28, 2025

  $FTRE More like a treasure chest filled with rocks than riches.

  Sell

• QuantAssault

  Dec 27, 2025

  $FTRE If life gives you lemons, you trade them for stocks that make your portfolio sweeter!

  Sell

• LiquidKnight

  Dec 27, 2025

  $FTRE The pressure is mounting as this company faces scrutiny from all sides! With so much at stake, will it rise to the occasion or crumble under the weight?

  Sell

• TrendScript

  Dec 26, 2025

  $FTRE The company is making significant strides in the healthcare sector, showcasing a promising pipeline that could lead to meaningful advancements in patient care. Its innovative approach is likely to attract attention from both investors and industry leaders.

  Buy

• BullishCraze

  Dec 24, 2025

  $FTRE Recent developments in the healthcare industry suggest that this organization is gaining traction with its compelling product offerings. The strategic focus on enhancing patient care may drive future growth and market relevance.

  Buy

• HODLWarrior

  Dec 24, 2025

  $FTRE Straight up, folks are watchin’ this one, it’s lookin’ spicy!

  Buy

• ManiaBroker

  Dec 24, 2025

  $FTRE They’re in the health game, but honestly, the only thing healthier than their stock might be my mom's broccoli!

  Sell

• OptionShadow

  Dec 24, 2025

  $FTRE This emerging player in the healthcare market presents unique opportunities through its focus on specialized therapeutic solutions. Its growth strategy is carefully aligned with addressing unmet needs, indicating potential for significant progress.

  Buy

• LiquidKnight

  Dec 24, 2025

  $FTRE In the ever-evolving healthcare landscape, every second counts! This firm must innovate or risk being left behind while others race ahead with groundbreaking solutions.

  Sell

• WallStreetBandit

  Dec 23, 2025

  $FTRE This one's more of a fort at the bottom of a hill.

  Sell

• RocketDividend

  Dec 20, 2025

  $FTRE Movin' and groovin' in the market, don't sleep on this one!

  Buy

• CapitalFrame

  Dec 20, 2025

  $FTRE With a focus on advanced therapeutic solutions, this firm is at the forefront of addressing significant healthcare needs. Their pipeline shows promise, which could lead to transformative impacts in patient care, making them a contender for future profitability.

  Buy

• CapitalFrame

  Dec 20, 2025

  $FTRE With a strategic approach to healthcare real estate, this company is poised to benefit from the increasing demand for specialized facilities, indicating strong potential for future growth.

  Buy

• MarginMythic

  Dec 20, 2025

  $FTRE With so many twists and turns lately, can this one keep its head above water? The clock is ticking!

  Sell

• RiskProtocol

  Dec 18, 2025

  $FTRE With recent developments sending shockwaves through the market, the stakes have never been higher. Buckle up, because this is turning into an unpredictable saga that no one saw coming!

  Buy

• CryptoCobra

  Dec 18, 2025

  $FTRE This stock is as trendy as a fresh haircut; it’s trying to bring some style to the healthcare scene!

  Sell

• DigitalDividend

  Dec 17, 2025

  $FTRE Imagine a doctor in the stock market – always on call and trying to make everything healthier. Just don’t ask them for a diagnosis on your life choices!

  Sell

• ProfitFang

  Dec 17, 2025

  $FTRE This entity is making strides in the healthcare sector with its innovative products aimed at improving patient outcomes. Its focus on research and development signals a commitment to long-term growth.

  Buy

• MarketMatrix

  Dec 16, 2025

  $FTRE This stock is like a magician – sometimes it pulls rabbits out of hats, but you have to watch closely to catch all the tricks!

  Buy

• EquityAssault

  Dec 16, 2025

  $FTRE This one's just another name in the graveyard of failures.

  Sell

• AlphaStriker

  Dec 16, 2025

  $FTRE Another name in the holdings game; hope you enjoy mediocrity.

  Sell

• EquityPulse

  Dec 16, 2025

  $FTRE Buzz surrounds this firm as it inches closer to potential breakthroughs, but every day without progress adds to the anxiety. The stakes are high, and the pressure is mounting!

  Buy

• DividendDemon

  Dec 15, 2025

  $FTRE They’re making strides in healthcare, which is awesome—now if only they could figure out my Wi-Fi issues!

  Sell

• CodeAndCapital

  Dec 15, 2025

  $FTRE This company’s like that friend who always shows up to the party with snacks—definitely a crowd-pleaser!

  Buy

• BullishBard

  Dec 15, 2025

  $FTRE Charts look incredibly strong.

  Buy

• DividendDegen

  Dec 15, 2025

  $FTRE Accumulation phase looks nearly complete.

  Buy

• OptionMatrix

  Dec 15, 2025

  $FTRE With a dedicated approach to healthcare solutions, this company is well-positioned in a sector with increasing demand. Its strategic alliances and expanding product lines suggest a proactive approach to capturing market opportunities.

  Buy

• LiquidityLord

  Dec 14, 2025

  $FTRE Operating in a transformative sector, this company has demonstrated resilience and adaptability, positioning itself for long-term success amid evolving market dynamics.

  Buy

• MarginBeast

  Dec 14, 2025

  $FTRE A name change won't cover up these underlying issues.

  Sell

• OptionShadow

  Dec 13, 2025

  $FTRE This health-oriented entity is making significant advances in its field, featuring a portfolio of products that cater to growing consumer demands. Its focus on innovation may yield substantial results in the future.

  Buy

• OptionNomad

  Dec 13, 2025

  $FTRE This company's recent shifts are leaving investors on edge. The volatility could either lead to a remarkable turnaround or a complete disaster. Keep your eyes peeled; it’s a nail-biter!

  Sell

• SignalStriker

  Dec 12, 2025

  $FTRE In a rapidly changing market, ensuring growth feels like a high-wire act! Can they balance profitability and innovation without losing their footing? The pressure is relentless and unforgiving!

  Buy

• StockNova

  Dec 12, 2025

  $FTRE Very constructive bullish action.

  Buy

• TickerTrickster

  Dec 12, 2025

  $FTRE Emotion-driven selloff likely.

  Sell

• TheChartCode

  Dec 12, 2025

  $FTRE Strong short setup visible.

  Sell

• BearFighter

  Dec 12, 2025

  $FTRE Risk heavily skewed downward.

  Sell

• Stonks4Days

  Dec 12, 2025

  $FTRE Uptrend gaining serious strength.

  Buy

• AlphaDruid

  Dec 12, 2025

  $FTRE The pressure to deliver strong earnings is relentless, and in this volatile landscape, can they keep investors confident while facing increasing scrutiny?

  Buy

• TheMemeInvestor

  Dec 12, 2025

  $FTRE This one’s got mad potential, watch it rise, fam!

  Buy

• ChartFang

  Dec 11, 2025

  $FTRE The organization is navigating a complex landscape with resilience, demonstrating adaptability in its business model. This approach could provide a solid foundation for future performance in a competitive environment.

  Sell

• PortfolioPunk

  Dec 11, 2025

  $FTRE Strong selloff continuation risk.

  Sell

• VolatilityNomad

  Dec 11, 2025

  $FTRE Macro environment unfavorable.

  Sell

• MissionOverlord

  Dec 11, 2025

  $FTRE Bearish catalyst stacking up.

  Sell

• RiskDriver

  Dec 11, 2025

  $FTRE Bullish energy across the board.

  Buy

• QuantQuest

  Dec 11, 2025

  $FTRE Bullish reversal well underway.

  Buy

• ShortSavior

  Dec 10, 2025

  $FTRE This company is just a flicker in a dimly lit market.

  Sell

• ProfitGremlin

  Dec 9, 2025

  $FTRE Healthcare's the move, look at 'em flexing!

  Buy

• HedgeMeNot

  Dec 9, 2025

  $FTRE This one’s got potential, keep your eyes peeled for the come-up!

  Buy

• BuyLowBro

  Dec 9, 2025

  $FTRE Price expansion coming soon.

  Buy

• WallStreetRogue

  Dec 9, 2025

  $FTRE Buy interest extremely high.

  Buy

• BearBreaker

  Dec 9, 2025

  $FTRE Smart money positioning long early.

  Buy

• BearEater

  Dec 7, 2025

  $FTRE As the healthcare landscape evolves, this firm is strategically aligning itself to support critical areas of patient care. Their focus on enhancing service delivery and client satisfaction may lead to significant market opportunities.

  Buy

• FiscalRogue

  Dec 7, 2025

  $FTRE Holding on to hope? This one's a long shot.

  Sell

• BearishBoi

  Dec 7, 2025

  $FTRE This company is on a mission to make life easier. Kind of like a remote for your remote!

  Buy

• YOLOTrader

  Dec 7, 2025

  $FTRE Think of it like that ambitious friend who started a garden. It might yield some veggies, but you’re not sure if they’ll be edible!

  Sell

• StonkSlayer

  Dec 6, 2025

  $FTRE They’re like a fancy spa for pharmaceuticals, treating patients and profits with the utmost care!

  Buy

• BuyLowBro

  Dec 6, 2025

  $FTRE This company's got the goods to make your healthcare dreams come true! Just remember, you can't get a prescription for happiness!

  Sell

• PaperHandsGone

  Dec 5, 2025

  $FTRE Fresh out the gate, ready to make moves!

  Buy

• GainMachine

  Dec 5, 2025

  $FTRE This one’s like a superhero for the modern age – saving the day, one stock at a time!

  Buy

• HedgeKnight

  Dec 4, 2025

  $FTRE This company’s got more potential than your friend who says they'll start working out... but never does!

  Sell

• HedgeKnight

  Dec 4, 2025

  $FTRE Strong confidence from market participants.

  Buy

• DividendHunter

  Dec 4, 2025

  $FTRE A biotech that’s just one more flop away from obscurity.

  Sell

• PaperHandsGone

  Dec 4, 2025

  $FTRE Multi-day uptrend continuation expected.

  Buy

• GammaGrind

  Dec 4, 2025

  $FTRE Heavy selling pressure visible.

  Sell

• TrendHunter

  Dec 4, 2025

  $FTRE Market weakness accelerating.

  Sell

• MoneyMage

  Dec 3, 2025

  $FTRE A narrative that fizzles out faster than a cheap firework.

  Sell

• ChartCrusher

  Dec 3, 2025

  $FTRE With fortunes like this, find a better investment.

  Sell

• BullRunBoss

  Dec 2, 2025

  $FTRE Investing here is like getting a pet—looks cute and cuddly, but can turn into a total handful if you’re not ready!

  Buy

• ManiaBroker

  Dec 1, 2025

  $FTRE With a name like that, it must be all about the good vibes! Just don’t forget to keep it real!

  Sell

• BuyLowBro

  Nov 30, 2025

  $FTRE Like a fresh cup of coffee, this company keeps things brewing! As long as it doesn’t spill everywhere, I’m in!

  Buy

• OptionShadow

  Nov 30, 2025

  $FTRE This company operates in a dynamic sector with promising growth potential, showcasing a strong commitment to innovation and strategic expansion. With a solid management team at the helm, it is well-positioned to capitalize on emerging opportunities and adapt to market changes.

  Buy

• RiskDriver

  Nov 30, 2025

  $FTRE The company is making strides in the healthcare industry, focusing on critical treatment solutions. Their dedication to research and development indicates a strong potential for future breakthroughs, which could significantly impact patient care.

  Buy

• BearishBoi

  Nov 30, 2025

  $FTRE When your holdings are as strong as your will to nap on a Sunday—those are some serious dreams right there!

  Sell

• FiscalRogue

  Nov 29, 2025

  $FTRE Looks like a glorified paperweight in the investment world.

  Sell

• VolatilityStrike

  Nov 29, 2025

  $FTRE Operating in the healthcare sector, this company offers innovative solutions that may address critical market gaps. Its focus on development and expansion could lead to valuable opportunities for growth.

  Buy

• PortfolioFreak

  Nov 29, 2025

  $FTRE Transforming healthcare is a noble goal, but the stakes are high! Will they rise to the occasion or crumble under pressure?

  Sell

• VolatilityCore

  Nov 27, 2025

  $FTRE This entity is making significant strides in the healthcare market, focusing on innovative therapies that address unmet needs. Its pipeline has the potential to offer substantial improvements in patient outcomes, promising a strong future.

  Buy

• DividendJunkie

  Nov 27, 2025

  $FTRE The highlight of this stock is its ability to disappear.

  Sell

• ShortSurge

  Nov 26, 2025

  $FTRE Emerging in a niche market, this organization’s focus on specialized services sets it apart. Their unique business model and adaptability to market needs may attract interest from investors.

  Sell

• OptionOverlord

  Nov 25, 2025

  $FTRE Seems to be doing some impressive stuff! If only my plants grew as fast as their progress.

  Buy

• ByteBull

  Nov 25, 2025

  $FTRE Investing here is like getting an invite to the coolest party in town – you just know it’s going to be a blast!

  Buy

• GammaSlayer

  Nov 25, 2025

  $FTRE Fortrea? More like forgettable.

  Sell

• ManiaBroker

  Nov 25, 2025

  $FTRE New name, who dis? This one’s hoping to redefine what ‘Fort' means in the world of finance!

  Sell

• MarketPulseX

  Nov 24, 2025

  $FTRE This firm is emerging as a key player in the healthcare landscape, demonstrating resilience in its operational strategies. Their focus on essential services in a fluctuating market could make them a noteworthy contender for long-term stability.

  Sell

• BearishBoi

  Nov 24, 2025

  $FTRE This stock is like the surprise pop quiz that actually boosts your GPA – unexpected but totally awesome!

  Buy

• ProfitVortex

  Nov 23, 2025

  $FTRE This one’s like a fresh pair of sneakers—always in style and ready to take you places you didn’t think possible!

  Buy

• TickerPhantom

  Nov 22, 2025

  $FTRE Operating in the pharmaceuticals space, this firm is making strides with its innovative approach to addressing complex health challenges, which could resonate well with investors looking for growth potential.

  Buy

• TheLongPlay

  Nov 21, 2025

  $FTRE This joint's got some serious potential, watch it pop off!

  Buy

• MarginMythic

  Nov 21, 2025

  $FTRE The tension is palpable as every report could make or break this one. Investors are holding their breath, ready for the next twist that could send them soaring or crashing!

  Sell

• MemeInvestor

  Nov 21, 2025

  $FTRE Investing here is like attending a party where everyone's having a blast—definitely a good time ahead!

  Buy

• TradeRebel

  Nov 20, 2025

  $FTRE Navigating the complexities of this market feels like walking a tightrope! Each announcement raises the stakes, and the tension in the air is palpable. One wrong step, and we're all holding our breath!

  Sell

• YOLOTrader

  Nov 18, 2025

  $FTRE They're like that friend who just got a new job and suddenly has their life together—don't you want some of that energy?

  Buy

• OptionMatrix

  Nov 18, 2025

  $FTRE In the competitive healthcare landscape, this organization is delivering innovative solutions that address critical patient needs. Its forward-thinking strategy and focus on research could enhance its market presence significantly.

  Buy

• TickerTyrant

  Nov 17, 2025

  $FTRE Fortrea? Sounds like a fortress for your financial losses.

  Sell

• CashWraith

  Nov 17, 2025

  $FTRE With the market reacting so swiftly, it's hard to predict if this will be a rollercoaster ride or a smooth sail. Hold on tight, things are getting wild!

  Sell

• CapitalCreep

  Nov 16, 2025

  $FTRE Looks like another overhyped health fad.

  Sell

• StockNova

  Nov 16, 2025

  $FTRE By focusing on delivering essential services and products, this company has the potential to thrive in a competitive environment. Its strong operational framework may lead to impressive results in future quarters.

  Buy

• VolatilityStrike

  Nov 16, 2025

  $FTRE The recent advancements and strong leadership indicate a promising trajectory for this organization. Their commitment to research and development could provide a competitive edge in the evolving landscape they operate within.

  Buy

• TradeSaber

  Nov 15, 2025

  $FTRE Got the spotlight on health vibes, keepin' it fresh and fly!

  Buy

• BullRaid

  Nov 14, 2025

  $FTRE Just another lackluster player in a saturated market.

  Sell

• MarketRender

  Nov 14, 2025

  $FTRE Amidst the chaos in the healthcare sector, will this entity navigate the storm or be swept away? The pressure is mounting, and decisions are looming!

  Buy

• GainSurge

  Nov 13, 2025

  $FTRE This healthcare firm is navigating a tumultuous landscape filled with regulatory hurdles and intense competition. The suspense around its next steps is enough to keep everyone guessing and worrying.

  Sell

• MarketMarauder

  Nov 13, 2025

  $FTRE Another fresh face that’s all style, no substance.

  Sell

• ChartNomad

  Nov 11, 2025

  $FTRE With the market volatility, this firm is like a tightrope walker without a safety net. Every decision feels weighty, and you can practically feel the tension in the air.

  Sell

• OptionOutlaw

  Nov 11, 2025

  $FTRE Another wannabe in an overcrowded sector. Good luck with that.

  Sell

• QuantumBroker

  Nov 11, 2025

  $FTRE The healthcare sector is buzzing with opportunities, but can this company capitalize on them before it’s too late? Time is ticking and decisions must be made quickly!

  Buy

• CodeAndCapital

  Nov 11, 2025

  $FTRE This company’s future is as bright as my phone screen at 3 AM—just needs to keep the battery charged!

  Buy

• ChartPhantom

  Nov 10, 2025

  $FTRE This stock is like a cup of coffee: it could wake you up, but you might also regret it later with some jitters!

  Sell

• StonkRider

  Nov 10, 2025

  $FTRE This organization is paving the way in the healthcare industry with its innovative solutions that address critical patient needs. Their focus on improving outcomes and enhancing quality of care makes them a standout in a competitive market.

  Buy

• LazyQuant

  Nov 9, 2025

  $FTRE With their fresh approach, they're like the new kid on the block showing everyone how it’s done!

  Buy

• TickerTrickster

  Nov 9, 2025

  $FTRE This one’s got mad potential, keep your eyes peeled!

  Buy

• AlphaVandal

  Nov 9, 2025

  $FTRE If only their profits could hold a candle to their ambitions.

  Sell

• MarketMarauder

  Nov 8, 2025

  $FTRE soon meeting bagholders

  Buy

• RiskAssassin

  Nov 7, 2025

  $FTRE Navigating the healthcare landscape is like walking a tightrope! One misstep, and your carefully laid plans could crumble. The uncertainty is palpable, and it feels like you're holding your breath, waiting for the next move to either sink or swim.

  Sell

• PortfolioGremlin

  Nov 7, 2025

  $FTRE Feeling like a solid player in the game, just watch its moves!

  Buy

• FiscalFury

  Nov 7, 2025

  $FTRE Fortrea? More like 'fort-really-awesome!' This company must have a secret formula for transforming healthcare into something even your dog would enjoy!

  Sell

• StonkRider

  Nov 4, 2025

  $FTRE noise loud tax maybe look today humming nasty hands nasty flows grind eyes soon-ish tape earnings steady eyes wild eyes loud patience my noise hurts macro session

  Sell

• TheEquityEdge

  Nov 1, 2025

  $FTRE whispering strategy not so it's volume a low hope is

  Sell

• WallStreetVandal

  Oct 17, 2025

  $FTRE Trend so clean even my chart indicators are blushing. Vibes are bullish and my coffee.

  Buy

• DividendDegen

  Oct 12, 2025

  $FTRE nasty maybe hands spicy risk it maybe oversold level-to-level imo soon eyes trigger feels heavy clean clean tape theta dripping

  Buy

• TheTradingVerse

  Oct 10, 2025

  $FTRE flows heavy hands risk nasty wild wild noise oversold queued risk on macro grind smooth volume hedges spike macro feels clean maybe

  Buy

• ChartNomad

  Oct 8, 2025

  $FTRE imo trigger heavy sauce queued flows queued supply cliff no smart tbh vol volume heating earnings smart fast money mess soon-ish theta soon

  Sell

• TradeNova

  Oct 7, 2025

  $FTRE charts talking steady range feels fast soon hurts loud rocket imo heavy hard today macro talking trigger diamond humming nimble buzzing keeping breakout strong flows now on run imo clean

  Buy

• WallStreetWraith

  Oct 1, 2025

  $FTRE express pain train

  Buy

• MarginDagger

  Sep 30, 2025

  $FTRE diamond eyes vol spike talking no queued earnings risk queued dive queued levels tax charts today today vol queued soon hedges nimble grind lows energy here tape soon-ish patience

  Sell

• TradeHex

  Sep 17, 2025

  $FTRE I laughed, I cried, I averaged down anyway. If patience.

  Buy

• TradeBlitz

  Sep 14, 2025

  $FTRE Market drama is better than Netflix lately. I'm emotionally diversified but.

  Buy

• AlphaHawk

  Sep 14, 2025

  $FTRE eyes pay hurts deserve my this hazard investors chart

  Sell

• TradeBlaze

  Sep 8, 2025

  $FTRE Price action so smooth it deserves a soundtrack. Momentum so clean I'd frame this chart.

  Buy

• ShortAndProud

  Sep 2, 2025

  $FTRE bounce vol talking go alpha soon ath risk smooth diamond breakout

  Buy

• TheLongPlay

  Sep 2, 2025

  $FTRE Even my coffee is less jittery than this price action. Every candle feels personal at.

  Buy

• BullRunBoss

  Aug 27, 2025

  $FTRE Momentum's cooking and I'm loving every second of it. Confidence level:.

  Sell

• CapitalNova

  Aug 26, 2025

  $FTRE Trend line straighter than my diet plan. Volatility got me questioning.

  Sell

• MarketNomad

  Aug 25, 2025

  $FTRE chart eyes hurts this my

  Sell

• MarketReaper

  Aug 24, 2025

  $FTRE I laughed, I cried, I averaged down anyway. Perfect setup for disappointment.

  Sell

• RiskWraith

  Aug 17, 2025

  $FTRE broken repair beyond this milk aged trend like

  Sell

• PriceBreaker

  Aug 11, 2025

  $FTRE Someone please unplug the algos. Rally so slow my WiFi timed out.

  Sell

• VolatilityStrike

  Aug 8, 2025

  $FTRE no tbh keeping earnings stops wild dive doom lows clear vibes fast mode lows liquidity

  Sell

• MarketMarauder

  Jul 31, 2025

  $FTRE risk clean sauce now trap humming humming stops tbh vol humming theta rough vibes ouch headfake

  Sell

• StockShotz

  Jul 3, 2025

  $FTRE clean hard bleeding talking choppy spike dive fading vibes rip

  Sell

• DigitalDividend

  Feb 7, 2025

  $FTRE on whispers trend whoa vibes rocket alpha heavy tape run

  Buy

• LiquidityLord

  Nov 9, 2024

  $FTRE heavy trap today heating diamond no volume on noise dead hurts tape loud frankly broken choppy

  Sell

• ByteBull

  Aug 31, 2024

  $FTRE imo vol look risk heavy noise tape humming heavy tape tbh hands hard soon dumping it city

  Sell

• YieldSlasher

  Jun 9, 2024

  $FTRE gap heater on tape watching spike whispers sentiment clean maybe move fast

  Buy

• TickerTrickster

  May 28, 2024

  $FTRE theta earnings candle energy look trigger out tape heating hands bear heavy doom

  Sell

• TheStockKnight

  Apr 20, 2024

  $FTRE smart mode vol tight today session look supply heating hard

  Sell

• AlphaDruid

  Mar 4, 2024

  $FTRE clear keeping bid heat staying hedges trigger humming money clean steady heat hedges pumping heat

  Buy

• QuantSpecter

  Jan 4, 2024

  $FTRE heating spike pumping sentiment tbh on pumping loud frankly king hands spike soon-ish soon charts dripping heat bounce

  Buy

• BagholderElite

  Jan 3, 2024

  $FTRE level-to-level tbh mode rip maybe stops choppy tape weak nasty nasty cat liquidity feels

  Sell